FLT3 inhibitors
Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
... on FLT3 inhibitors in AML induction/salvage ...AND FLT3 OR tyrosine kinase inhibitor OR sorafenib OR sunitinib OR midostaurin OR lestaurtinib OR quizartinib OR crenolanib, without restrictions on the ...
18
Clinical use of FLT3 inhibitors in acute myeloid leukemia
... of FLT3-ITD delivers poor ...on FLT3 inhibitor use to improve the outcomes of this otherwise difficult ...in FLT3-mutated AML in the frontline setting. Several FLT3 inhibitors, ...
12
FLT3 inhibitors: clinical potential in acute myeloid leukemia
... pertinent FLT3 TKI, as accumulated evidences pinpointed that AML cells may be addicted to FLT3-ITD-dependent ...encompass FLT3 TKD amino acid substitutions, bypass activation of oncogenic kinases, ...
9
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
... the FLT3 alterations can be secondary mutations arising in an already malignant clone, with selection of the subclone containing the FLT3 mutation because of the growth or survival advantage it ...acquired ...
7
FLT3 inhibitors in acute myeloid leukemia
... dual FLT3/AXL inhibi- ...of FLT3/ITD-positive leukemia cells ...of FLT3 and its downstream targets in cell cultures as well as in animal ...in FLT3-mutated patients at doses ≥ 80 ...mutated ...
11
Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
... and FLT3 inhibitors are of particular clinical interest in AML: both rpS6 dephosphorylation and dynamic BH3 profiling had been able to predict response to these drugs (S1 ...
17
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3 -ITD mutated acute myeloid leukemia
... with FLT3- ITD achieve a transient remission, they often suffer early relapse with emergence of treatment resistance ...Several FLT3 inhibitors (sorafenib, midostaurin (PKC-412), quizartinib (AC220), ...
16
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
... SET inhibitors, in combination with TKIs and/or standard chemotherapy, is a potential therapeutic strategy for ...of FLT3-ITD signalling, and inhibition of Pim kinases was synergistic with FLT3 ...
14
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
... of FLT3 inhibitors. The localization of Wt- FLT3 and ITD- FLT3 enable us to explain this different response to FL ...of FLT3 with glycosylation is necessary for cell surface ...of ...
15
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
... to FLT3 inhibition, the effects of inhibitors such as quizartinib have been well described, with myelosuppression being one of the most prominent toxicities, likely due to the com- bined inhibition of both ...
17
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
... Various inhibitors for the PI3K/Akt pathway have shown only modest effects on AML cells, including those with FLT3-ITD, in preclinical and clinical studies, which may be partly explained by alternative ...
17
Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
... with FLT3 mutation are characterized with high relapse rate and short ...with FLT3-ITD have a high relapse rate and short relapse-free and overall survival after chemotherapy and after transplant ...[2]. ...
12
An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
... The FLT3 receptor is mutated in about thirty percent of patients with ...domain. FLT3-ITD mutations confer a poor prognosis and, in these patients, FLT3 is a validated therapeutic target [1, ...
11
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
... of FLT3 by using a protein substrate ...on FLT3 and its FLT3D835Y and FLT3 D835H mutant forms (data not ...type FLT3 with an IC 50 value of ...
6
Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity
... kinase inhibitors on FLT3 and its ...these inhibitors are listed in Table ...of FLT3 activity at ...these FLT3-inhibitory compounds are known to tar- get multiple proteins kinases and ...
5
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
... of FLT3/ITD and TKD mutations [17]. Oral tyrosine kinase inhibitors (TKI) are widely used for targeted therapy of chronic myeloid leukemia and myeloproliferative neoplasms ...[18–21]. FLT3/ITD and ...
6
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
... [45]. FLT3 inhibition is one of the major promising targeted therapies in this ...expressing FLT3-ITD suggested that the expression of this receptor induced myeloproliferative neoplasms rather than AML, ...
18
Abundance of Flt3 and its ligand in astrocytic tumors
... Intermediate expression of ligand in astrocytic tumors would have a functional impact only in the presence of its corresponding receptor, ie, Flt3. However, the abundance of the receptor mRNA turned out to be much ...
7
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
... [20]. FLT3 is reported to be expressed on HPSCs and gran- ulocyte/macrophage progenitor (GMP) stages and per- forms important roles in maintaining the survival of stem and progenitor cells ...of FLT3 were ...
12
Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
... The migration capacity can be related to cell mechanics. Very recently, we introduced RT-DC, which allows on-the-fly analysis of deformed cell shape [29]. Using this technology, we provide evidence for decreased ...
12